Results 71 to 80 of about 7,085 (151)
Expression and Clinical Significance of mTOR and PTEN in Non-small Cell Lung Cancer [PDF]
, 2010 Background and objective It has been proved that mTOR was an important signal transduction molecular and protein kinase regulating cell growth and proliferation, and mTOR could activate the downstream protein effector. PTEN could negatively regulate mTOR
Liang WANG +5 more
core
CEA、CYFRA21-1、NSE、CA125联合检测在肺癌诊断中的价值
Zhongguo shiyan zhenduanxue, 2014 目的评价血清癌胚抗原（CEA）、细胞角蛋白19片段（CYFRA21-1）、神经元特异性烯醇化酶（NSE）、糖类抗原125（CA125）在肺癌诊断中的作用及其联合检测的临床价值。方法选取500例肺癌患者,分为鳞癌、腺癌和小细胞癌3组,采用电化学发光法检测并分析各组间及和50例健康对照组血清CEA,CYFRA21-1,NSE,CA125水平。结果肺癌组的各项肿瘤标志物水平较健康对照组差异具有统计学意义 ...
王文涛, 张国俊
doaj
Clinical Application of Adjuvant Treatment after Operation in Patients with Stage IIIa Non-small Cell Lung Cancer [PDF]
, 2010 Background and objective The efficacy of complete resection of the cancer for patients with stage IIIa non-small cell lung cancer (NSCLC) is limited. Synthetic therapy is taken the lead in advocating at present.
Bin ZHANG, Xia ZHANG, Yajie GAO
core
Zhongguo shiyan zhenduanxue, 2018 研究发现程序性死亡因子-1(PD-1)、程序性死亡1-配体(PD-L1)在多种肿瘤细胞和肿瘤组织中均有表达,如黑色素瘤、非小细胞肺癌、肾母细胞瘤等,肿瘤组织中过度表达的PD-L1通过与PD-1结合下调抗肿瘤免疫反应[1,2]。目前已有多种免疫药物在临床上应用于多种恶性肿瘤,如pembrolizumab是一种高亲和力的结合PD-1的人源化IgG4-kappa抗体用于治疗晚期黑色素瘤,muvolumab用于治疗鳞状细胞肺癌,并取得美国食品药品管理局(FDA)通过及认证[3 ...
王耿杰 +3 more
doaj
Immediate Versus Delayed Topotecan after First-line Therapy in Small Cell Lung Cancer [PDF]
, 2010 Background and objective How to prolong progression free survival (PFS) and overall survival (OS) of patients with small cell lung cancer (SCLC) has been one of the hottest issues. We retrospectively reviewed our data to compare the survival of immediate
Cong XUE +7 more
core
Zhongguo shiyan zhenduanxue, 2007 目的探讨肺癌肿瘤标记物手术前后变化及其临床意义。方法选经手术治疗25例肺癌患者,监测术前和术后第8天的肿瘤标记物CA125、CA153、CEA和AFP、的变化。结果术后CA125、CA153和CEA水平较术前减低,而AFP手术前后变化不大。结论通过监测肿瘤标记物水平改变可以协助肺癌手术疗效的判断,具有简便、经济的特点,在临床中具有一定的价值。
齐红, 崔焕波, 席妍
doaj
The Impact of Smoking Status on the Efficacy of Erlotinib in Patients with Advanced Non-small Cell Lung Cancer [PDF]
, 2009 Background and objective Erlotinib is a targeted treatment for advanced non-small cell lung cancer. Smoking status may be one of influencing factors of the efficacy of erlotinib.
Jinji YANG +5 more
core
Zhongguo shiyan zhenduanxue, 2010 目的探讨纤维支气管镜刷检与CT下肺穿刺细胞学对肺癌及其分型的诊断价值。方法对331例患者纤维支气管镜、肺穿涂片,进行瑞-吉氏染色、检验,对结果进行统计、分析,并记录其病理学结果 ,同时对肿瘤标志物CEA、CYFRA21-1、NSE进行检测。结果 331例中肺癌患者140例,细胞学诊断结果敏感性为85.7%,特异性为88.2%,符合率85.7%,其中肺腺癌78.9%,肺鳞癌64.3%,小细胞癌87.1%。肺腺癌肿瘤标志物CEA与对照组、鳞癌组及小细胞癌组比较 ...
赵成艳, 王敏, 何晓琳, 项南
doaj
The Role of Postoperative Radiotherapy on Stage N2 Non-small Cell Lung Cancer [PDF]
, 2009 Background and objective The clinical value of postoperative radiotherapy (PORT) in stage N2 nonsmall-cell lung cancer (NSCLC) is controversy. The aim of this study is to analyze the efficacy of PORT in subgroup of stage N2 NSCLC, which can help ...
Changli WANG +7 more
core
Zhongguo shiyan zhenduanxue, 2015 肺硬化性血管瘤(scerosing hemangioma of the lung,SHL)是肺内的一种至今仍不能完全确定其组织来源和性质的少见肿瘤,易与肺腺癌、炎性假瘤等混淆,诊断率低,易误诊。因此,本文对36例硬化性血管瘤的临床资料、病理特征进行分析,以提高对本病的认识。1资料与方法1 ...
邹玉凤 +5 more
doaj